For the first time, there is something to prescribe.
For generations, those caught in the grip of methamphetamine addiction faced a medicine cabinet with nothing to offer them — only willpower and behavioral support stood between them and the drug. In early 2026, a clinical trial published in JAMA Psychiatry quietly closed that gap, finding that mirtazapine, a humble generic antidepressant already stocked in pharmacies worldwide, meaningfully reduced methamphetamine use among people struggling to quit. The discovery does not promise a cure, but it offers something the field has never had before: a proven, affordable, accessible pharmacological foothold in a disorder that has claimed millions of lives.
- Methamphetamine use disorder has long been a pharmacological orphan — 7.4 million people worldwide affected, and until now, not a single approved medication to treat it.
- The Tina Trial enrolled 339 heavily dependent adults using crystal meth on roughly 24 out of every 28 days, setting a high-stakes stage for what would become a landmark result.
- Mirtazapine produced a statistically meaningful edge — seven fewer days of use per month versus 4.8 for placebo — a modest but clinically significant reduction that lowers risks of heart attack, stroke, and psychosis.
- The drug's dual action on depression and insomnia addresses the underlying conditions that often fuel the cycle of use, opening the door to more integrated mental health care.
- Because mirtazapine is cheap, globally available, and already proven safe, it can move from research finding to routine prescription without the usual barriers of cost, scarcity, or regulatory novelty.
For decades, physicians treating methamphetamine addiction had no pharmaceutical tool to offer — only counseling, rehabilitation, and the patient's own resolve. That changed in early 2026 when researchers at UNSW Sydney published results from the Tina Trial in JAMA Psychiatry, revealing that mirtazapine, a widely available generic antidepressant, significantly reduced methamphetamine use in people trying to quit.
The trial followed 339 adults with moderate to severe methamphetamine use disorder across six Australian outpatient clinics. Participants were using crystal methamphetamine — the drug's most potent form — on roughly 24 days out of every 28. Half received 30 milligrams of mirtazapine daily for 12 weeks; the other half received placebo. Those on mirtazapine reduced their use by seven days per month, compared to 4.8 days in the placebo group — translating to eight fewer use days per 100 possible days, a difference that carries real consequences for cardiovascular health, infection risk, and mental stability.
The stakes are considerable. Methamphetamine use disorder affects an estimated 7.4 million people globally, with chronic use linked to heart attack, stroke, kidney failure, psychosis, and premature death. Chief investigator Professor Rebecca McKetin described the finding as a game-changer — not because it cures addiction, but because it works and because it is already accessible. Side effects were limited to drowsiness and weight gain, with no unexpected safety concerns.
What gives mirtazapine particular promise is its dual utility. Many people with methamphetamine use disorder also suffer from depression and insomnia — conditions the drug already treats — allowing clinicians to address multiple problems with a single, affordable prescription. For many trial participants, the study marked the first time they had spoken openly with a doctor about their drug use, creating openings for broader care they had long been avoiding.
Mirtazapine will not resolve the addiction crisis. But for the first time, people who want to stop using crystal methamphetamine have a proven medication waiting for them — one that is inexpensive, globally manufactured, and already sitting on pharmacy shelves.
For decades, there has been no medication to treat methamphetamine addiction. Doctors could offer counseling, support groups, rehabilitation programs—but nothing pharmaceutical. That changed in early 2026 when researchers at UNSW Sydney published results from the Tina Trial in JAMA Psychiatry, showing that mirtazapine, a generic antidepressant available in pharmacies worldwide, significantly reduced methamphetamine use in people trying to quit.
The trial enrolled 339 adults with moderate to severe methamphetamine use disorder across six outpatient clinics in Australia. At the start, participants were using crystal methamphetamine—the purest, most potent form of the drug—on roughly 24 days out of every 28. Half received 30 milligrams of mirtazapine daily for 12 weeks. The other half received placebo. The difference in outcome was clear: those on mirtazapine reduced their use by seven days per month, compared to a 4.8-day reduction in the placebo group. In practical terms, that's an 8 percent decrease in the risk of use—eight fewer days of methamphetamine consumption out of 100 possible use days.
The stakes of this finding are substantial. Methamphetamine use disorder affects an estimated 7.4 million people worldwide. The drug is highly addictive, and chronic use carries devastating health consequences: heart attack, stroke, kidney failure, hepatitis C, HIV, psychosis, suicide, and premature death. Until now, there was no pharmacological intervention. People struggling with addiction had to rely entirely on behavioral treatment and willpower.
What makes mirtazapine particularly valuable is its accessibility. It is cheap, already manufactured and distributed globally, and has a well-established safety profile developed over decades of use as an antidepressant. It can be prescribed in routine clinical settings with minimal oversight. Professor Rebecca McKetin, the chief investigator, called it a game-changer—not because it cures addiction, but because it works and because it is available. "This is not a silver bullet," she said, "but it's a very important step forward and will encourage people struggling with methamphetamine use to seek support."
The side effects were modest. More participants in the mirtazapine group reported drowsiness and weight gain than those on placebo, but no unexpected safety concerns emerged. Associate Professor Shalini Arunogiri, an addiction psychiatrist and study co-author, emphasized that even small reductions in use matter. When someone cuts their methamphetamine consumption by a week per month, their risk of heart attack, stroke, and infection drops. Their sleep improves. Their mood stabilizes. For many trial participants, this was the first time they had spoken to a doctor about their drug use—an opening that allowed clinicians to address other health needs they had been neglecting.
There is another dimension to mirtazapine's effectiveness. Many people with methamphetamine use disorder also struggle with depression and insomnia. The drug addresses both the addiction and the underlying mood and sleep disturbances that often perpetuate the cycle of use. This allows for what Arunogiri called a more integrated treatment approach—one medication that tackles multiple problems at once.
The trial was a collaboration across four Australian universities and health services in six cities. The results are being published at a moment when methamphetamine use is rising in many countries and when the absence of any pharmacological treatment has left clinicians with limited tools. Mirtazapine will not solve the addiction crisis. But for the first time, people who want to stop using crystal methamphetamine have access to a medication that works, that is affordable, and that is already sitting on pharmacy shelves.
Citas Notables
This is not a silver bullet but it's a very important step forward and will encourage people struggling with methamphetamine use to seek support.— Professor Rebecca McKetin, chief investigator
Even small reductions in methamphetamine use can translate into meaningful improvements in health and well-being.— Associate Professor Shalini Arunogiri, addiction psychiatrist
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that this is the first medication proven to work for methamphetamine addiction?
Because for 7.4 million people worldwide, there has been literally nothing. No pill, no injection, no pharmacological option. Doctors could only offer talk therapy and support. Now there's something concrete to prescribe.
But the reduction is modest—seven days versus 4.8 days. Does that really change someone's life?
Yes. One fewer week of use per month means one fewer week of strain on your heart, one fewer week of risk for stroke or kidney failure. And psychologically, it's a foothold. It's proof that you can reduce use. It opens a door to other help.
Why mirtazapine specifically? Why not design something new?
Because it already exists. It's cheap, safe, and doctors know how to use it. You don't need years of development and approval. You can prescribe it tomorrow in any clinic. That's the genius of it.
What about the side effects—drowsiness and weight gain?
They're real, but they're manageable. And they're far less dangerous than the consequences of continued methamphetamine use. Most people would take drowsiness over the risk of psychosis or a heart attack.
You mentioned that many people on mirtazapine also have depression. Is the drug treating the addiction or the depression?
Both. That's what makes it elegant. Methamphetamine use and depression feed each other. The drug breaks that cycle. It's not a silver bullet, but it's a tool that addresses multiple problems at once.
What happens next?
Doctors start prescribing it. People who want to quit have a real option. And researchers keep looking for ways to make treatment even more effective.